CRSP
Closed
Crispr Therapeutics Ag
48.51
-0.13 (-0.27%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 48.64
Day's Range: 46.6 - 49.92
Send
sign up or login to leave a comment!
When Written:
45.23
Crispr Therapeutics AG is a biotechnology company that is focused on developing gene editing therapies using the CRISPR/Cas9 technology. The company was founded in 2013 by Emmanuelle Charpentier, Jennifer Doudna, and Rodger Novak. The company is headquartered in Zug, Switzerland, and has research and development facilities in Cambridge, Massachusetts.
Crispr Therapeutics AG is developing gene editing therapies for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. The company's lead product candidate is CTX001, a gene therapy for the treatment of sickle cell disease and beta thalassemia. The company is also developing gene therapies for the treatment of Duchenne muscular dystrophy, cystic fibrosis, and other genetic disorders.
Crispr Therapeutics AG has partnerships with several pharmaceutical companies, including Vertex Pharmaceuticals, Bayer AG, and ViaCyte. The company is also collaborating with academic institutions, including the University of California, Berkeley, and the Max Planck Institute for Infection Biology.
Crispr Therapeutics AG went public in 2016 and is traded on the NASDAQ stock exchange under the ticker symbol CRSP. The company has a market capitalization of over $10 billion as of September 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Crispr Therapeutics AG is developing gene editing therapies for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. The company's lead product candidate is CTX001, a gene therapy for the treatment of sickle cell disease and beta thalassemia. The company is also developing gene therapies for the treatment of Duchenne muscular dystrophy, cystic fibrosis, and other genetic disorders.
Crispr Therapeutics AG has partnerships with several pharmaceutical companies, including Vertex Pharmaceuticals, Bayer AG, and ViaCyte. The company is also collaborating with academic institutions, including the University of California, Berkeley, and the Max Planck Institute for Infection Biology.
Crispr Therapeutics AG went public in 2016 and is traded on the NASDAQ stock exchange under the ticker symbol CRSP. The company has a market capitalization of over $10 billion as of September 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!